Direct anti-biofilm effects of macrolides on Acinetobacter baumannii: comprehensive and comparative demonstration by a simple assay using microtiter plate combined with peg-lid.


Journal

Biomedical research (Tokyo, Japan)
ISSN: 1880-313X
Titre abrégé: Biomed Res
Pays: Japan
ID NLM: 8100317

Informations de publication

Date de publication:
2020
Historique:
entrez: 3 12 2020
pubmed: 4 12 2020
medline: 1 10 2021
Statut: ppublish

Résumé

Recently, opportunistic nosocomial infections caused by Acinetobacter baumannii have become increasingly prevalent worldwide. The pathogen often establishes biofilms that adhere to medical devices, causing chronic infections refractory to antimicrobial therapy. Clinical reports have indicated that some macrolide antibiotics are effective against chronic biofilm-related infections. In this study, we examined the direct anti-biofilm effects of seven macrolides (azithromycin, clarithromycin, erythromycin, josamycin, spiramycin, fidaxomicin, and ivermectin) on A. baumannii using a simple and newly established in vitro assay system for the swift and serial spectrophotometric determinations of two biofilm-amount indexes of viability and biomass. These macrolides were found to possess direct anti-biofilm effects exerting specific anti-biofilm effects not exclusively depending on their bacteriostatic/bactericidal effects. The anti-biofilm effect of azithromycin was found to be the strongest, while those of fidaxomicin and ivermectin were weak and limited. These results provide insights into possible adjunctive chemotherapy with macrolides for A. baumannii infection. Common five macrolides also interfered with the Agrobacterium tumefaciens NTL(pCF218) (pCF372) bioassay system of N-acyl homoserine lactones, providing insights into sample preparation for the bioassay, and putatively suggesting the actions of macrolides as remote signals in bacterial quorum sensing systems.

Identifiants

pubmed: 33268670
doi: 10.2220/biomedres.41.259
doi:

Substances chimiques

Acyl-Butyrolactones 0
Anti-Bacterial Agents 0
Erythromycin 63937KV33D
Ivermectin 70288-86-7
Spiramycin 8025-81-8
Azithromycin 83905-01-5
Clarithromycin H1250JIK0A
Josamycin HV13HFS217
Fidaxomicin Z5N076G8YQ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

259-268

Auteurs

Kaoru Yamabe (K)

Graduate School of Public Policy, The University of Tokyo.

Yukio Arakawa (Y)

Department of Social and Administrative Pharmacy, Osaka University of Pharmaceutical Sciences.

Masaki Shoji (M)

Department of Social and Administrative Pharmacy, Osaka University of Pharmaceutical Sciences.

Mitsuko Onda (M)

Department of Social and Administrative Pharmacy, Osaka University of Pharmaceutical Sciences.

Katsushiro Miyamoto (K)

Department of Microbiology and Infection Control, Osaka University of Pharmaceutical Sciences.

Takahiro Tsuchiya (T)

Department of Microbiology and Infection Control, Osaka University of Pharmaceutical Sciences.

Yukihiro Akeda (Y)

Division of Infection Control and Prevention, Graduate School of Medicine, Osaka University.

Kuniko Terada (K)

Department of Pharmacy, Osaka Rosai Hospital.

Kazunori Tomono (K)

Division of Infection Control and Prevention, Graduate School of Medicine, Osaka University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH